I mean, we've

never done enough for investors, but we try our best.

So I would say a lot of the early work was in animal studies to make sure that our technologies are reliable, that they work well.

So there's a lot of iterative work there, going from small animal models like rats up to non-human primates before going into humans.

Then there's a lot of bench testing, biocompatibility testing, things like that, that we need to do a lot of testing before we go into humans.

So I would say that's a big part of de-risking is really on the technology itself.

But another big aspect of de-risking is also on the markets and then the clinical needs.

is that tinnitus

Where are you at and what's your kind of current thinking on your long-term roadmap of where you go with this?

So it's interesting because when we started, Neuralink had just barely started.

And so we were still thinking about what we're building as a kind of a single indication medical device company.

And indeed, we spent a lot of time trying to find what is the key indication.

And so tinnitus was one of these kind of huge unmet clinical needs.

Still up to date, I still believe this is a very strong on medical need where you have patients who have these ringing in the ear, extremely severe, like a lot of them attempt to commit suicide due to depression.

It's really, really horrible.

Which again, interesting on many levels, but to the headline reader, people will be like, aren't they your competitor? Don't you compete with those guys? But talk a bit about that partnership and how, I guess, the BCI value chain is already starting to fragment along specialist lines, and this alliance illustrates that.